Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials
Alicia Okines(Royal Marsden NHS Foundation Trust), Andrew Wotherspoon(Université Libre de Bruxelles), Jonathan Wadsley(Weston Park Cancer Centre), Ruth E. Langley(MRC Clinical Trials Unit at UCL), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust), Marcia Hall(Hillingdon Hospitals NHS Foundation Trust), Angus Robinson(Royal Sussex County Hospital), Justin S. Waters(Maidstone Hospital), Sally Stenning(Medical Research Council), Ian Chau(Universitat Autònoma de Barcelona), Gary Middleton(University of Birmingham), Lindsay C Thompson(Medical Research Council), David Cunningham(Royal Marsden NHS Foundation Trust), L. Puckey(Royal Marsden NHS Foundation Trust), Daniel Swinson(St James's University Hospital), Claire Saffery(Royal Marsden NHS Foundation Trust), Jorge S. Reis‐Filho(Memorial Sloan Kettering Cancer Center), Zakaria Eltahir(Royal Marsden NHS Foundation Trust), Yolanda Barbáchano(Royal Marsden NHS Foundation Trust), David González de Castro(Complejo Hospitalario de Salamanca), Tom Samuel Waddell(Royal Marsden NHS Foundation Trust), D. Ferry(University Hospitals Birmingham NHS Foundation Trust), David B. Smith(Wirral University Teaching Hospital NHS Foundation Trust), Sanna Hulkki Wilson(Royal Marsden NHS Foundation Trust), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), T. Crosby(Velindre Cancer Centre), Michael Band(Royal Marsden NHS Foundation Trust)
Cited by 40
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations
|New England Journal of Medicine|2015|1.7k